Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
NCT03927443 · Sun Pharmaceutical Industries Limited · PHASE3 · withdrawn · last registry update 2021-11-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\[Sponsors decision\]” | – | Registry record, Sun Pharmaceutical Industries Limited |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-17Phase 3 first posted: Otsuka Beijing Research Institute, OPC-1085EL + 0.005% Latanoprost (NCT05583474)
- 2022-08-24Phase 3 first posted: South Valley University, Latanoprost 0.005% Ophthalmic Solution + 5Fluorouracil (NCT05513924)
- 2022-08-10Phase 3 first posted: Santen Pharmaceutical Co., Ltd., STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005% (NCT05495061)
- 2022-06-02Phase 3 first posted: Amneal Pharmaceuticals, LLC, Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) (NCT05401357)
- 2022-05-31Phase 3 first posted: Laboratoires Thea, Bimatoprost Ophthalmic (NCT05397600)
- 2022-05-10Results posted on the registry: MediPrint Ophthalmics, Inc., LL-BMT1 (NCT04747808)
- 2022-02-23Results posted on the registry: Allergan, Bimatoprost SR + Sham Bimatoprost SR (NCT02636946)
- 2022-01-19Results posted on the registry: Aerie Pharmaceuticals, Netarsudil/Latanoprost 0.02%/0.005% + GANFORT® (NCT03284853)
- 2021-12-21Phase 3 first posted: TearClear Corp, Latanoprost ophthalmic solution, 0.005% + TC-002 latanoprost ophthalmic solution, 0.005% (NCT05165290)
- 2021-10-11Results posted on the registry: Ocular Therapeutix, Inc., Travoprost (NCT02914509)
- 2021-08-23Results posted on the registry: Icahn School of Medicine at Mount Sinai, Latanoprost 0.005% + Latanoprost bunod 0.024% (NCT03949244)
- 2021-07-28Results posted on the registry: Allergan, Bimatoprost SR + Active Comparator: Timolol 0.5% (NCT02250651)
- 2021-06-21Also stopped (withdrawn): West Virginia University, Latanoprost ophthalmic solution + Timolol ophthalmic solution (NCT03648229)
- 2021-05-24Phase 3 first posted: Laboratoires Thea, Bimatoprost Timolol (T4030) + Bimatoprost Timolol (Ganfort) (NCT04898387)
- 2021-05-18Phase 3 first posted: Mankind Pharma Limited, Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) (NCT04890106)
- 2021-05-03Results posted on the registry: Pfizer, PF-04217329 + latanoprost vehicle (NCT00934089)
- 2021-04-30Results posted on the registry: Pfizer, PF-04217329 - Lowest Dose + PF-04217329 - Low Dose (NCT00572455)
- 2021-03-05Results posted on the registry: Tulane University, bimatoprost 0.03% ophthalmic solution (NCT02830776)
- 2021-02-02Also stopped (withdrawn): Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Xalatan (NCT00143429)
- 2021-02-02Also stopped (withdrawn): Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Xalatan (NCT00283764)
- 2020-12-01Results posted on the registry: Université de Sherbrooke, Brand name travoprost + Generic travoprost (NCT02796560)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision